Protai has built an AI-based platform that maps the course of diseases on the protein level, enhancing the ability to observe cellular function and discover new drugs. By systematically mapping diseases on the protein level the company aims to create an entirely new layer of functional information that enables identification of therapeutic and diagnostic targets. […]

NonExomics is focused on the non-exome regions of the genome and has identified hundreds of potential new drug targets across rare diseases, neuropsychiatric disorders, and cancer. The parts of our DNA that code for proteins make up around 2% of the human genome and are collectively known as the exome. The exome is the best […]

Amyl Therapeutics is Belgian preclinical biotech company developing a technology platform to bind various types of amyloid fibrils and induce their clearance, potentially offering a breakthrough approach to treating protein misfolding diseases. Amyloidosis is a group of diseases characterized by an endogenous production of misfolded proteins that aggregate as insoluble amyloid fibrils and form deposits […]

Resalis Therapeutics is a biopharma company focused on the development of antisense oligonucleotide (ASO) therapies to treat metabolic disorders, including MAFLD/NAFLD/NASH, obesity, and cancer. Resalis is applying LNA (locked nucleic acid) technology to inhibit miR-22 activity and restore a healthy homeostat in livers affected by metabolic disorders. miR-22 is a key player in the regulation […]

Comanche Biopharma is developing novel siRNA (Small interfering RNA) compounds to treat preeclampsia via gene silencing. The protein sFLT-1 is believed to be the cause of preeclampsia. This protein, produced by the placenta and measurable in the plasma of pregnant women, is both diagnostic and prognostic for preeclampsia and is causally responsible for its disease […]

NextRNA Therapeutics was founded in 2020 to pursue non-coding RNAs as a new class of therapeutic target for diseases including cancer, infectious diseases, and autoimmune disorders. There are many RNAs that do not make proteins, called non-coding RNAs (ncRNA). These ncRNAs are able to regulate essential processes and when altered cause disease. NextRNA has developed […]

Anturec Pharmaceuticals is a German anticancer drug development company which was founded in 2020 based on research carried out at University Hospital Muenster. The company’s target is aminopeptidase N (CD13) located on cells of the tumor vasculature and some tumor cells, but absent from most mature blood vessels. The company’s founders have designed and studied […]

Founded in 2020, Signet Therapeutics is developing targeted small molecule cancer drugs using novel disease models. Dr. Haisheng Zhang, CEO of Signet Therapeutics, and his core team members originate from Dana-Farber Cancer Institute, Harvard Medical School. The company says that traditional in vitro studies use cell lines that cannot accurately model patient’s drug performance, often […]

Quris is developing a fully automated, self-training AI platform designed to better predict clinical safety and efficacy for new drug candidates. The company is pioneering clinical trials on chips, which involves testing thousands of novel drug candidates on hundreds of stem-cells-derived “patients-on-a-chip”. Its fully automated, self-training AI platform is designed to accurately predict clinical safety […]

Founded in 2020, Regain Therapeutics is pursuing a new treatment approach for Alzheimer’s disease which focuses on replenishing soluble amyloid-beta peptides in the brain rather than removing the corresponding accumulation of amyloid plaques. The company has been founded based on research discoveries and patent-pending technologies developed at Karolinska Institute in Sweden in collaboration with The […]

Ancilia Biosciences develops novel bacterial therapies that target the viral components of the microbiome to address chronic diseases across immunology and oncology indications. The company is developing a proprietary platform that leverages the natural function of CRISPR to produce a new class of live biotherapeutics (LBPs) with engineered immunity to viral phages. These viral phages, […]

Kanvas Bioscience wants to revolutionize microbial research and infectious disease diagnostics with next generation imaging technology that is able to provide deeper information on the spacial organisation and behaviour of microbial communities. The company’s highly multiplexed imaging technology originates from Cornell University and uses a two-step process called high phylogenetic resolution microbiome mapping by fluorescence […]

Bo InnoHealth is a spin-off from the Hong Kong Polytechnic University developing a novel microencapsulation technology which can protect probiotics and probiotics and enable their use in a wider range of applications such as snacks, hot drinks and pet food. The company’s approach is based on using mushroom cells as a protective material to make […]

Talus Bio aims to revolutionize drug development for gene regulators by enabling the ability to study gene regulatory proteins (GRPs) in a living cell environment. The company’s initial focus is on small-molecule drug development in oncology. Founded in 2020 as a spin out of the University of Washington and Altius Institute for Biomedical Sciences, the […]

Founded in 2020, iTolerance is regenerative medicine company developing a potential cure for Type 1 Diabetes that eliminates the need for chronic immunosuppression of patients. The company’s lead program, ITOL-101, is an adjunct therapy with pancreatic islet cell implant currently in development for the treatment of or as a potential breakthrough cure for Type 1 […]

Leyden Labs is developing broad spectrum antivirals that target commonalities of viral families, potentially offering protection against known viruses as well as new viruses as they emerge. The company was founded in 2020 in response to the COVID-19 pandemic by Koenraad Wiedhaup, a former partner at McKinsey & Co, and three previous executives of Crucell, […]

Originating from the Wyss Institute for Biologically Inspired Engineering at Harvard University, Unravel Biosciences has developed a vertically integrated computational platform to discover better drug targets. Instead of classic pharma, which takes a target of interest and develops drugs to bind that specific target, Unravel’s platform screens many drugs in parallel for their real-world impact […]

Vernal Biosciences is aiming to democratize access to mRNA manufacturing technologies, with the goal of accelerating the clinical impact of mRNA as a foundational therapeutic modality. Vernal is focused on achieving and maintaining high purity throughout the scaling of all mRNA manufacturing processes for clients in the research and ultimately clinical stages. The company wants […]

AVVantgarde Bio is a gene therapy startup that has developed two adeno-associated viral (AAV)-based platforms with increased transfer capabilities to enable the delivery of large genes. Gene therapy based on AAV vectors has proven effective for several forms of genetic blindness, however the small vector payload may limit their further application. The company’s two AAV-based […]

Kuano is aiming to transform the discovery of enzyme inhibitor drugs using a platform that combines quantum transition state simulation and AI led chemistry. Enzyme catalysis occurs via thermodynamically favoured quantum transition states, which represent an attractive conformation for targeting enzyme inhibitors. Kuano’s proprietary in silico approach rapidly simulates the quantum transition state and generates […]